Mathijs Bunck
Company: Eli Lilly & Company
Job title: Associate Vice President, Medical Development, Tirzepatide Obesity
Seminars:
Chair’s Closing Remarks 4:30 pm
day: Day Two
Scaling the Chasm of Diagnosis & Patient Enrolment to Improve Meaningful Recruitment & Retention 1:00 pm
day: Day 2 Stream 2 PM
Innovating Clinical Trial Design to Engage Patients & Optimize Study Outcome 10:45 am
day: Day 2 Stream 2 AM
Panel Discussion: Agents, Trial Design & Collaboration: Breaking New Ground in Combination Therapy with Multiple Mechanisms of Action 9:30 am
Navigating different combinations of therapeutic agents: what can you combine? Crafting protocols around current standard for care Collaborate to innovate: examining rationale for cross-industry partnerships to forge synergistic combination therapiesRead more
day: Day One
Tirzepatide, Morbidity & Mortality in Obesity: Pioneering a Holistic Approach to Obesity Outcomes Trials 8:30 am
Investigating an unprecedented step forward in weight loss: development of the dual GIP and GLP-1 receptor agonist tirzepatide Moving beyond traditional outcome trials for individual indications to efficiently assess efficacy in obesity, HFpEF, NASH, CKD, and other obesity-related morbidities Navigating a broader primary endpoint and select type-1 error controlled secondary endpoints to study multiple outcomes…Read more
day: Day One